Lähdeaho et al. [20] investigated the safety and efficacy of AMG 714, an anti-IL-15 monoclonal antibody, also known as PRV-015, in patients with CeD undergoing a gluten challenge, showing no change in the villous height–crypt depth (Vh:Cd) ratio from baseline after 12 weeks of treatment between the placebo and treated groups. The gene discussed is IL15; the disease is cranioectodermal dysplasia.